ArticleMolecular and cellular pharmacology2009
Anti-Inflammatory Agents for Cancer Therapy.
Article in Molecular and cellular pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed, 1 synthesis or guideline pooled it, 340 citations in OpenAlex.
- Non-oncologic to oncologic drug: A systematic review of drug repurposing in cancer.Cancer chemotherapy and pharmacology · 2025Pooled it
- The role of prostanoids in the retina and optic nerve in health and disease.Progress in retinal and eye research · 2026Review
- In-silico studies, synthesis, and pharmacological screening of novel multitarget diphenylpyrazole scaffold as EGFR/BRAF and cyclooxygenase-2 inhibitors.Scientific reports · 2025Article
- Discovering the Anti-Inflammatory Potential of Compounds Isolated from the Aerial Parts ofMolecules (Basel, Switzerland) · 2025Article
- Article
- Ibuprofen-Functionalized Alkyl α-hydroxy Methacrylate-Based Polymers.ChemistryOpen · 2025Article
- Multi spectroscopic investigation of maisine-based microemulsions as convenient carriers for co-delivery of anticancer and anti-inflammatory drugs.Scientific reports · 2025Article
- Cracking the code: the clinical and molecular impact of aminopyridines; a review (2019-2024).RSC advances · 2025Review
- The Pattern of Anemia in Pediatric Solid Tumors Prior to and after Chemotherapy- A Retrospective Cohort Study.Current cancer drug targets · 2025Article
- Repurposing of Indomethacin and Naproxen as anticancer agents: progress from 2017 to present.RSC advances · 2024Review
- Gold(I) Complexes Based on Nonsteroidal Anti-Inflammatory Derivatives as Multi-Target Drugs against Colon Cancer.Inorganic chemistry · 2024Article
- Article
- Fermentation impact: A comparative study on the functional and biological properties of Banana peel waste.Heliyon · 2024Article
- Unveiling the multifaceted antiproliferative efficacy ofRSC advances · 2024Article
- Article
- Review
- Modification of ibuprofen to improve the medicinal effect; structural, biological, and toxicological study.Heliyon · 2024Article
- Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy.Pharmaceutics · 2024Article
- Prodigiosin/celecoxib-loaded into zein/sodium caseinate nanoparticles as a potential therapy for triple negative breast cancer.Scientific reports · 2024Article
- Recent Advancements in Refashioning of NSAIDs and their Derivatives as Anticancer Candidates.Current pharmaceutical design · 2024Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Inflammation is closely linked to cancer, and many anti-cancer agents are also used to treat inflammatory diseases, such as rheumatoid arthritis. Moreover, chronic inflammation increases the risk for various cancers, indicating that eliminating inflammation may represent a valid strategy for cancer prevention and therapy. This article explores the relationship between inflammation and cancer with an emphasis on epidemiological evidence, summarizes the current use of anti-inflammatory agents for cancer prevention and therapy, and describes the mechanisms underlying the anti-cancer effects of anti-inflammatory agents. Since monotherapy is generally insufficient for treating cancer, the combined use of anti-inflammatory agents and conventional cancer therapy is also a focal point in discussion. In addition, we also briefly describe future directions that should be explored for anti-cancer anti-inflammatory agents.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.